

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-26. (Canceled)

27. (Currently amended) A peptide composition comprising a peptide molecule consisting of about forty amino acids or less and comprising a peptide sequence selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13), GSGSGPRHRDGVRRPQKRP (SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16), GTGAGAGARGRG (SEQ ID NO:17), SGRGRGG (SEQ ID NO:18), RGGSGRRGRGR (SEQ ID NO:19), RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID NO:21), RPPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID NO:23), GPSTGRPG (SEQ ID NO:25), GQGDGGRK (SEQ ID NO:26), DGGRKKGGWFGKHR (SEQ ID NO:27), GKHRGQGSN (SEQ ID NO:28), GQGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31), VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID NO:34), PQGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVCSEDDG (SEQ ID NO:37), PPWFPPMVEG (SEQ ID NO:38) and combinations thereof ~~or portions thereof sufficient to react with autoantibody~~, wherein the peptide is present either in free form or bound to a carrier molecule.

28. (Canceled)

29. (Currently amended) The composition of claim 27, wherein the peptide molecule or molecules are in a pharmaceutically acceptable carrier ~~for administration of the composition in an amount and mode effective to induce tolerance to EBV associated immune responses.~~

25480555.1

30. (Currently amended) The ~~peptide-molecules~~composition of claim 27 mobilized to a solid support.
31. (Currently amended) The ~~peptide-molecules~~composition of claim 27 labeled with a detectable label.
32. (Currently amended) The ~~peptide-molecules~~composition of claim 30 immobilized to multiwell plates.
33. (Currently amended) The ~~peptide-molecules~~composition of claim 30 immobilized to a gel suitable for affinity chromatography.
34. (Currently amended) The ~~peptide-molecules~~composition of claim 27 bound by autoantibodies in patients characterized by specific disorders.
35. (Previously presented) A method for determining the likelihood that an individual has or will develop an autoimmune disorder comprising screening their antibodies for reactivity with a peptide molecule consisting of about forty amino acids or less and comprising a peptide sequence selected from the group consisting of PPPGRRP (SEQ ID NO:1), GRGRGRGG (SEQ ID NO:2), RGRGREK (SEQ ID NO:3), GAGAGAGAGAGAGAGAGAGAGA (SEQ ID NO:7), GPQRRGGDNHGRGRGRGRGRGGGRPG (SEQ ID NO:13), GGSGSGPRHRDGVRRPQKRP (SEQ ID NO:14), RPQKRPS (SEQ ID NO:15), QKRPSIGCKGTHGGTG (SEQ ID NO:16), GTGAGAGARGRGG (SEQ ID NO:17), SGGRGRGG (SEQ ID NO:18), RGGSGGRRGRGR (SEQ ID NO:19), RARGRGRGRGEKRPRS (SEQ ID NO:20), SSSSGSPRRPPPGR (SEQ ID NO:21), RPPPGRRPFFHPVGEADYFEYHQEG (SEQ ID NO:22), PDVPPGAI (SEQ ID NO:23), PGAIEQGPA (SEQ ID NO:24), GPSTGRPG (SEQ ID NO:25), GQGDGGRRK (SEQ ID NO:26), DGGRKKGGWFGKHR (SEQ ID NO:27), GKHRGQGGSN (SEQ ID NO:28), GQGGSNPK (SEQ ID NO:29), NPKFENIA (SEQ ID NO:30), RSHVERTT (SEQ ID NO:31), VFVYGGSKT (SEQ ID NO:32), GSKTSLYNL (SEQ ID NO:33), GMAPGPGP (SEQ ID NO:34), PQGPLRE (SEQ ID NO:35), CNIRVTVC (SEQ ID NO:36), RVTVC SFDDG (SEQ

ID NO:37), PPWFPPMVEG (SEQ ID NO:38) and combinations ~~or portions~~ thereof ~~sufficient to react with autoantibody~~, wherein the peptide is present in either free form or bound to a carrier molecule.

36. (Previously presented) The method of claim 35 wherein the peptide molecules are immobilized to a solid support.

37. (Previously presented) The method of claim 35 wherein the peptide molecules are labeled with a detectable label.

38. (Previously presented) The method of claim 35 wherein the peptide molecules are immobilized to multiwell plates.

39. (Previously presented) The method of claim 35 wherein the peptide molecules are immobilized to a gel suitable for affinity chromatography.

40. (Previously presented) The method of claim 35 wherein the peptide molecules are bound by autoantibodies.